Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group and its partner Hangzhou Innogate Pharma have secured approval from China’s National Medical Products Administration to begin clinical trials of SYH2095 tablets, a first-in-class KAT6 inhibitor for advanced malignant tumours. The drug, an epigenetic anticancer agent that has already received U.S. FDA clearance for trials, showed strong tumour growth suppression and a favourable safety profile in preclinical studies, positioning CSPC at the forefront of a new oncology target with no existing approved therapies worldwide.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing and commercializing innovative drugs, particularly in oncology and other therapeutic areas. The group collaborates with research partners to advance novel therapies aimed at both domestic and international markets.
YTD Price Performance: -7.71%
Average Trading Volume: 86,789,208
Technical Sentiment Signal: Buy
Current Market Cap: HK$89.5B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.